Axicabtagene Ciloleucel

The FDA published a safety advisory on the risk of T-cell malignancies among individuals receiving autologous chimeric antigen receptor T-cell therapy for the treatment of certain blood cancers.

Second-line therapy with axicabtagene ciloleucel induced a complete metabolic response in 71% of adults with relapsed or refractory large B-cell lymphoma ineligible for autologous stem cell transplant, results of a phase 2 study showed.

Now that chimeric antigen receptor T-cell therapy has become part of the treatment landscape in hematologic malignancies, researchers are focused on developing more potent, less toxic agents that can be used in earlier treatment settings.

In this video, Joshua Brody, MD, discusses an update of the ZUMA-7 trial, which was presented at ASCO Annual Meeting.

CHICAGO — Second-line therapy with axicabtagene ciloleucel conferred a significant increase in OS compared with the current standard of care among adults with relapsed or refractory large B-cell lymphoma, results of the randomized phase 3 ZUMA-7 study showed.

Individuals living with HIV historically have been at higher risk for non-Hodgkin lymphoma.

Patients with hematologic malignancies reported significant improvement in quality of life after receiving chimeric antigen receptor T cells, results from a longitudinal study in Blood Advances showed.

Axicabtagene ciloleucel significantly extended survival compared with historic standard of care in a curative setting for adults with previously untreated relapsed or refractory large B-cell lymphoma, according to the agent’s manufacturer.

Only a decade ago, many in oncology considered chimeric antigen receptor T-cell therapy too fringe for real-world use.

NEW ORLEANS — Chimeric antigen receptor T cells demonstrated acceptable efficacy with no additional safety concerns when administered to patients with non-Hodgkin lymphoma and HIV, retrospective study results showed.